Arbios Appoints Dr. Philip Rosenthal and Dr. Robert S. Brown, Jr. to Its Scientific Advisory Board
June 24 2005 - 9:00AM
PR Newswire (US)
Arbios Appoints Dr. Philip Rosenthal and Dr. Robert S. Brown, Jr.
to Its Scientific Advisory Board Top Thought Leaders in Liver
Disease to Play Important Role in the Development Strategy for
Arbios' Bioartificial Liver LOS ANGELES, June 24
/PRNewswire-FirstCall/ -- Arbios Systems, Inc. (OTC:ABOS) a
biomedical device company developing proprietary liver assist
devices for the treatment of liver failure, announced today that
the Company has appointed Drs. Robert S. Brown, Jr., M.P.H. and
Philip Rosenthal, to its Scientific Advisory Board. Commenting on
these latest appointments, Amy Factor, Chief Executive Officer of
Arbios, stated, "We are delighted to welcome Drs. Brown and
Rosenthal to our Scientific Advisory Board. They are highly
esteemed researchers and physicians in the liver disease arena, and
were involved in the Phase II/III clinical trials of
HepatAssist(TM), the predecessor version of our bioartificial
liver, currently under development. As a result of their specific
expertise, Drs. Brown and Rosenthal will play an important role in
the development of our clinical and regulatory strategy for our
bioartificial liver program. Dr. Brown is currently Associate
Professor of Medicine & Surgery and Chief, Division of
Hepatobiliary and Abdominal Transplant Surgery, Columbia University
College of Physicians & Surgeons. In addition, he is currently
Medical Director, Center for Liver Disease and Transplantation, New
York Presbyterian Hospital -- a position he has held since 1998.
Prior to joining Columbia University College of Physicians &
Surgeons, Dr. Brown was Medical Director of Liver Transplantation
at the University of North Carolina from 1996 to 1998. Dr. Brown's
research is focused on clinical trials and epidemiologic research
in liver failure and liver transplantation, particularly the
outcomes of living donor liver transplantation, artificial liver
support, and the management of viral hepatitis, areas in which he
has had extensive research funding from the NIH and industry. Dr.
Brown was a special section editor for Hepatology, serves on the
editorial board for Liver Transplantation and is a reviewer for the
journals: Transplantation, American Journal of Gastroenterology,
New England Journal of Medicine, and the International Journal of
Epidemiology, among others. He has published more than 80 original
articles, reviews and book chapters. Dr. Brown is a fellow in the
American College of Physicians and the American College of
Gastroenterology, and is a member of the American Society of
Transplantation, where he served as chair of the Liver and
Intestine Committee and the American Association for the Study of
Liver Disease (AASLD). He is currently co-chair of the United
Network for Organ Sharing ad hoc living donor committee. Dr. Brown
received his A.B. degree from Harvard University, his M.D. degree
from New York University, and his M.P.H. from the Graduate School
of Public Health at the University of California at Berkeley. He
completed a Fellowship in Gastroenterology and Hepatology at the
University of California, San Francisco. Dr. Rosenthal is an
internationally renowned children's liver disease specialist. He
currently serves as the Director of Pediatric Hepatology, Medical
Director of the Pediatric Liver Transplant Program and a Professor
of Pediatrics and Surgery at the University of California, San
Francisco (UCSF). He joined the UCSF faculty in 1995, after serving
as Professor of Pediatrics at the University of California, Los
Angeles (UCLA). Dr. Rosenthal is a prolific author and a recipient
of a number of professional honors and awards and is committed to
clinical service, research and education. Currently, he is pursuing
research on the pharmaceutical treatment of hepatitis B and C,
genetics and immunology of biliary atresia, use of bioartificial
liver support utilizing porcine hepatocytes for patients with
fulminant liver failure, as well as researching the quality of life
following liver transplantation in children. Dr. Rosenthal's
professional services to the public include television, newspaper
and radio interviews on various topics such as hepatitis A, B, and
C, and liver transplants for local, national and international
audiences. He is a consultant to organizations such as the American
Liver Foundation, Parents of Kids with Infectious Diseases, the
Alagille Syndrome Alliance, Studies of Pediatric Liver
Transplantation (SPLIT), the Centers for Disease Control and
Prevention (CDC) and the National Institute of Health (NIH). Dr.
Rosenthal is board certified in Pediatrics and Pediatric
Gastroenterology. He received a B.S. degree in Biology from the
State University of New York at Albany and completed his medical
training at Downstate Medical Center and the Albert Einstein
Medical Center in New York, after which he completed a fellowship
in pediatric gastroenterology at UCSF. Arbios Systems, Inc. is a
biomedical device company that, through its wholly owned
subsidiary, Arbios Technologies, Inc., is engaged in the discovery,
acquisition and development of proprietary liver assist devices and
new technologies useful in the diagnosis and treatment of acute
liver failure. Arbios' products in development include SEPET(TM), a
novel blood purification therapy and HepatAssist-2(TM), a
bioartificial liver combining liver cell therapy and sorbent-based
detoxification. This press release contains forward-looking
statements that involve risks and uncertainties that could cause
actual events or results to differ materially from the events or
results described in the forward-looking statements, including
risks or uncertainties related to obtaining clinical site
approvals, manufacturing SEPET(TM) cartridges, enrolling patients,
compliance with regulatory requirement, the results of the clinical
tests to be conducted by the company, the need for subsequent
substantial additional financing to complete clinical development
of its products, and Arbios' ability to successfully market its
products and technologies. These statements represent the judgment
of Arbios' management as of this date and are subject to risks and
uncertainties that could materially affect the company. The company
does not undertake any obligation to publicly release the result of
any revisions to such forward-looking statements that may be made
to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. SEPET(TM) and
HepatAssist-2(TM) are trademarks of Arbios Technologies, Inc., the
subsidiary of Arbios Systems, Inc. DATASOURCE: Arbios Systems, Inc.
CONTACT: Amy Factor, Chief Executive Officer, +1-973-377-7665, of
Arbios; or Paula Schwartz, Investors, +1-917-322-2216, or Pat
Garrison, Media, +1-917-322-2567, both of RX Communications Group
for Arbios Web site: http://www.arbios.com/
Copyright